$ANIK
Anika Therapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000117184321003272 Filed on May 07, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $34.29M $35.40M
YoY Change -3.12% 43.17%
Cost Of Revenue $13.32M $14.20M
YoY Change -6.21% 94.23%
Gross Profit $20.97M $21.20M
YoY Change -1.05% 21.74%
Gross Profit Margin 61.16% 59.88%
Selling, General & Admin $18.18M $14.43M
YoY Change 25.94% 88.1%
% of Gross Profit 86.65% 68.08%
Research & Development $6.361M $6.050M
YoY Change 5.14% 42.09%
% of Gross Profit 30.33% 28.54%
Depreciation & Amortization $3.510M $2.760M
YoY Change 27.17% 86.49%
% of Gross Profit 16.74% 13.02%
Operating Expenses $24.54M $20.48M
YoY Change 19.8% 71.68%
Operating Profit $1.258M $7.094M
YoY Change -82.27% 29.41%
Interest Expense -$43.00K $279.0K
YoY Change -115.41% -43.98%
% of Operating Profit -3.42% 3.93%
Other Income/Expense, Net
YoY Change
Pretax Income $1.215M $7.373M
YoY Change -83.52% 23.29%
Income Tax -$1.600M $1.600M
% Of Pretax Income -131.69% 21.7%
Net Earnings $2.838M $5.793M
YoY Change -51.01% 28.53%
Net Earnings / Revenue 8.28% 16.37%
Basic Earnings Per Share $0.20 $0.41
Diluted Earnings Per Share $0.20 $0.40
COMMON SHARES
Basic Shares Outstanding 14.34M 14.20M
Diluted Shares Outstanding 14.44M 14.35M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.60M $92.30M
YoY Change 2.49% -44.63%
Cash & Equivalents $94.60M $65.83M
Short-Term Investments $0.00 $26.50M
Other Short-Term Assets $9.600M $5.700M
YoY Change 68.42% 171.43%
Inventory $42.72M $42.72M
Prepaid Expenses
Receivables $26.51M $28.10M
Other Receivables $0.00 $0.00
Total Short-Term Assets $173.5M $161.1M
YoY Change 7.66% -23.16%
LONG-TERM ASSETS
Property, Plant & Equipment $49.13M $54.23M
YoY Change -9.41% 2.23%
Goodwill $8.045M $33.80M
YoY Change -76.2% 339.33%
Intangibles $88.99M $98.72M
YoY Change -9.86% 1065.91%
Long-Term Investments
YoY Change
Other Assets $20.29M $27.51M
YoY Change -26.23% 587.16%
Total Long-Term Assets $188.8M $237.8M
YoY Change -20.61% 145.23%
TOTAL ASSETS
Total Short-Term Assets $173.5M $161.1M
Total Long-Term Assets $188.8M $237.8M
Total Assets $362.3M $398.9M
YoY Change -9.19% 30.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.683M $9.906M
YoY Change -12.35% 177.4%
Accrued Expenses $13.30M $16.10M
YoY Change -17.39% 101.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $200.0K
YoY Change -50.0%
Total Short-Term Liabilities $46.97M $26.19M
YoY Change 79.37% 125.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.583M $1.019M
YoY Change 55.35% 178.42%
Total Long-Term Liabilities $1.583M $1.019M
YoY Change 55.35% 178.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.97M $26.19M
Total Long-Term Liabilities $1.583M $1.019M
Total Liabilities $48.56M $27.21M
YoY Change 78.47% 127.33%
SHAREHOLDERS EQUITY
Retained Earnings $224.3M $251.2M
YoY Change -10.72% 12.79%
Common Stock $57.43M $48.50M
YoY Change 18.4% -7.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $276.7M $293.7M
YoY Change
Total Liabilities & Shareholders Equity $362.3M $398.9M
YoY Change -9.19% 30.08%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income $2.838M $5.793M
YoY Change -51.01% 28.53%
Depreciation, Depletion And Amortization $3.510M $2.760M
YoY Change 27.17% 86.49%
Cash From Operating Activities -$2.431M $1.045M
YoY Change -332.63% -87.65%
INVESTING ACTIVITIES
Capital Expenditures $417.0K $723.0K
YoY Change -42.32% -29.81%
Acquisitions $350.0K $92.98M
YoY Change -99.62%
Other Investing Activities $2.150M -$91.78M
YoY Change -102.34% 10212.36%
Cash From Investing Activities $1.734M -$92.50M
YoY Change -101.87% 4725.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$451.0K -$141.0K
YoY Change 219.86% 18.49%
NET CHANGE
Cash From Operating Activities -$2.431M $1.045M
Cash From Investing Activities $1.734M -$92.50M
Cash From Financing Activities -$451.0K -$141.0K
Net Change In Cash -$1.218M -$91.63M
YoY Change -98.67% -1525.93%
FREE CASH FLOW
Cash From Operating Activities -$2.431M $1.045M
Capital Expenditures $417.0K $723.0K
Free Cash Flow -$2.848M $322.0K
YoY Change -984.47% -95.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Assets Current
AssetsCurrent
177383000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49131000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50613000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22325000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22619000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20292000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15420000 USD
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
88986000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
91157000 USD
CY2021Q1 us-gaap Goodwill
Goodwill
8045000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
8413000 USD
CY2021Q1 us-gaap Assets
Assets
362253000 USD
CY2020Q4 us-gaap Assets
Assets
365605000 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
8683000 USD
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14391261
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1411000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1523000 USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14366000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14366000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14329000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14329000
CY2020Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94599000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95817000 USD
CY2021Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2501000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26509000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24102000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
42718000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
46209000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9648000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8754000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
173474000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8984000 USD
CY2021Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13460000 USD
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14793000 USD
CY2021Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
24830000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
13090000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
46973000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36867000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1583000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1244000 USD
CY2021Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5760000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
22320000 USD
CY2021Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
10738000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
11895000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20543000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20879000 USD
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
144000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
143000 USD
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
57281000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
55355000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5051000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4542000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
224282000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
221444000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
276656000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
272400000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
362253000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
365605000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34292000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35397000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13318000 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14200000 USD
CY2021Q1 us-gaap Gross Profit
GrossProfit
20974000 USD
CY2020Q1 us-gaap Gross Profit
GrossProfit
21197000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6361000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6050000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18175000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14431000 USD
CY2021Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
18144000 USD
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-4820000 USD
CY2020Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-24522000 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
19716000 USD
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
14103000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1258000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
7094000 USD
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-43000 USD
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
279000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1215000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7373000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1623000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1580000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
2838000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
5793000 USD
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4040000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3632000 USD
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14343000
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14202000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14435000
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14353000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
2838000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
5793000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-509000 USD
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-129000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2329000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5664000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
272400000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1000 USD
CY2021Q1 anik Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit
APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit
2259000 USD
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
333000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
2838000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-509000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
276656000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
288378000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
0 USD
CY2020Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
-0 USD
CY2020Q1 anik Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit
APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit
-207000 USD
CY2020Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
141000 USD
CY2020Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
-0 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
5793000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-129000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
293694000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
2838000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
5793000 USD
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3508000 USD
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2761000 USD
CY2021Q1 anik Operating Lease Rightofuse Asset Amortization
OperatingLeaseRightofuseAssetAmortization
405000 USD
CY2020Q1 anik Operating Lease Rightofuse Asset Amortization
OperatingLeaseRightofuseAssetAmortization
340000 USD
CY2021Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
18144000 USD
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-4820000 USD
CY2020Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-24522000 USD
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-831000 USD
CY2020Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-0 USD
CY2021Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2020Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
318000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2259000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
-207000 USD
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1162000 USD
CY2020Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
550000 USD
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-21000 USD
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-15000 USD
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
277000 USD
CY2020Q1 us-gaap Inventory Write Down
InventoryWriteDown
831000 USD
CY2021Q1 anik Amortization Of Acquisition Related Inventory Step Up
AmortizationOfAcquisitionRelatedInventoryStepUp
2578000 USD
CY2020Q1 anik Amortization Of Acquisition Related Inventory Step Up
AmortizationOfAcquisitionRelatedInventoryStepUp
2081000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2478000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2004000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-87000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
445000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
188000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
421000 USD
CY2021Q1 anik Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-385000 USD
CY2020Q1 anik Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-310000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1254000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3233000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-1242000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
166000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2431000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1045000 USD
CY2021Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
350000 USD
CY2020Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
92983000 USD
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2501000 USD
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
14990000 USD
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
-0 USD
CY2020Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
13787000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
417000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
723000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1734000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-92503000 USD
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
332000 USD
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
141000 USD
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
119000 USD
CY2020Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
-0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-451000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-141000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-70000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-31000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1218000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-91630000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95817000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
157463000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
94599000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65833000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
570000 USD
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
55000 USD
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
220000 USD
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2021Q1 anik Consideration For Acquisitions Included In Accounts Payable And Accrued Expenses
ConsiderationForAcquisitionsIncludedInAccountsPayableAndAccruedExpenses
0 USD
CY2020Q1 anik Consideration For Acquisitions Included In Accounts Payable And Accrued Expenses
ConsiderationForAcquisitionsIncludedInAccountsPayableAndAccruedExpenses
2085000 USD
CY2021Q1 anik Acquisition Related Contingent Consideration
AcquisitionRelatedContingentConsideration
0 USD
CY2020Q1 anik Acquisition Related Contingent Consideration
AcquisitionRelatedContingentConsideration
69076000 USD
CY2021Q1 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
220000 USD
CY2020Q1 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
CY2021Q1 us-gaap Nature Of Operations
NatureOfOperations
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tbody> <tr> <td style="vertical-align: top; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">1.</em></b></p> </td> <td style="vertical-align: top; width: 96%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Nature of Business</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Anika Therapeutics, Inc. (“the Company”) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis (“OA”) pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In early <em style="font: inherit;">2020,</em> the Company expanded its overall technology platform through its strategic acquisitions of Parcus Medical, LLC (“Parcus Medical”), a sports medicine implant and instrumentation solutions provider focused on sports medicine and soft tissue repair, and Arthrosurface, Inc. (“Arthrosurface”), a company specializing in less invasive, bone preserving partial and total joint replacement solutions. These acquisitions broadened Anika's product portfolio, developed over its nearly <em style="font: inherit;">30</em> years of expertise in hyaluronic acid technology, into joint preservation and restoration, added high-growth revenue streams, increased its commercial capabilities, diversified its revenue base, and expanded its product pipeline and research and development expertise.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company is subject to risks common to companies in the biotechnology and medical device industries including, but <em style="font: inherit;">not</em> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There continue to be uncertainties regarding the pandemic of the novel coronavirus (“COVID-<em style="font: inherit;">19”</em>), and the Company is closely monitoring the impact of COVID-<em style="font: inherit;">19</em> on all aspects of its business, including how it will impact its customers, employees, suppliers, vendors, and business partners. The Company is unable to predict the specific impact that COVID-<em style="font: inherit;">19</em> <em style="font: inherit;"> may </em>have on its financial position and operations moving forward due to the numerous uncertainties. Any estimates made herein <em style="font: inherit;"> may </em>change as new events occur and additional information is obtained, and actual results could differ materially from any estimates made herein under different assumptions or conditions. The Company will continue to assess the evolving impact of COVID-<em style="font: inherit;">19.</em></p>
CY2021Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
34292000 USD
CY2020Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
39350000 USD
CY2021Q1 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
2838000 USD
CY2020Q1 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
6790000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0 USD
CY2020Q4 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
5000000 USD
CY2020Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
15565000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
14852000 USD
CY2020Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
11262000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
12811000 USD
CY2020Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
35336000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
33347000 USD
CY2020Q1 anik Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total
InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal
62163000 USD
CY2020Q4 anik Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total
InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal
61010000 USD
CY2020Q1 us-gaap Inventory Net
InventoryNet
42718000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
46209000 USD
CY2020Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
19445000 USD
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
14801000 USD
CY2021Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
112736000 USD
CY2021Q1 anik Accumulated Currency Translation Adjustment
AccumulatedCurrencyTranslationAdjustment
3088000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
20662000 USD
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
88986000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
91157000 USD
CY2020 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P13Y
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1900000 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 USD
CY2020 us-gaap Number Of Reporting Units
NumberOfReportingUnits
2 pure
CY2020Q4 us-gaap Goodwill
Goodwill
8413000 USD
CY2021Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-368000 USD
CY2021Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0 USD
CY2021Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
-0 USD
CY2021Q1 us-gaap Goodwill
Goodwill
8045000 USD
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
42500000 USD
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5726000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7345000 USD
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2904000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3438000 USD
CY2021Q1 anik Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1746000 USD
CY2020Q4 anik Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1429000 USD
CY2021Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
119000 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
148000 USD
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1448000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
996000 USD
CY2021Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13460000 USD
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14793000 USD
CY2021Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 USD
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
900000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
200000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34292000 USD
CY2021Q1 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1 pure
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35397000 USD
CY2020Q1 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1 pure
CY2021Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
92000
CY2020Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
151000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14435000
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14353000
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2259000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-207000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1600000 USD
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-1.336 pure
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600000 USD
CY2020Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.214 pure
CY2021Q1 anik Effective Income Tax Rate Reconciliationchange In Fair Value Of Business Acquisition Contingent Consideration Liabilities Amount
EffectiveIncomeTaxRateReconciliationchangeInFairValueOfBusinessAcquisitionContingentConsiderationLiabilitiesAmount
-1700000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
900000 USD
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14343000
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14202000

Files In Submission

Name View Source Status
0001171843-21-003272-index-headers.html Edgar Link pending
0001171843-21-003272-index.html Edgar Link pending
0001171843-21-003272.txt Edgar Link pending
0001171843-21-003272-xbrl.zip Edgar Link pending
anik-20210331.xsd Edgar Link pending
anik-20210331_cal.xml Edgar Link unprocessable
anik-20210331_def.xml Edgar Link unprocessable
anik-20210331_lab.xml Edgar Link unprocessable
anik-20210331_pre.xml Edgar Link unprocessable
anik20210331_10q.htm Edgar Link pending
anik20210331_10q_htm.xml Edgar Link completed
ex_244940.htm Edgar Link pending
ex_244941.htm Edgar Link pending
ex_244942.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending